International Journal of Clinical Practice · 1999 · 52 citations · 6 references
PharmacyPharmacologyPharmacotherapyCardiovascular PharmacotherapyClinical PharmacologyPharmacodynamicsBlood Pressure ManagementCough ManagementHypertension ManagementHypertension PharmacotherapyAngiotensin Ii Receptor BlockersAntihypertensive Drug TherapyAntihypertensive PharmacologyCough EfficacyEvaluation Of CoughRenin-angiotensin System BlockadeRenin-angiotensin-aldosterone System BlockadeRenin-angiotensin-aldosterone System Inhibition
SUMMARY Dry cough is a troublesome side‐effect associated with certain antihypertensive agents that act by modulating aspects of the renin‐angiotensin‐aldosterone system. The incidence of dry cough associated with two of these therapies, the novel All receptor antagonist telmisartan and the ACE inhibitor lisinopril, was assessed in a multicentre, randomised, parallel‐group, double‐blind, placebo‐controlled, 8‐week study of 88 patients with mild to moderate hypertension who previously demonstrated ACE inhibitor‐related cough. Patients received either telmisartan 80 mg, lisinopril 20 mg, or placebo once daily. Cough incidence, measured at each visit by a self‐administered symptom assessment questionnaire, was significantly higher with lisinopril (60%) than with telmisartan (15.6%) or placebo (9.7%). A visual analogue scale demonstrated a similar trend for cough frequency. Thus the incidence of cough with telmisartan 80 mg is significantly less than that seen with lisinopril 20 mg and is comparable to placebo.
6
Alan H. Gradman, Karen E. Arcuri, Allan I. Goldberg et al. · Hypertension · 1995 · 226 citations
The advantages of angiotensin II antagonism.
Michel Burnier, Bernard Waeber, Hans R. Brunner · PubMed · 1994 · 32 citations
Medicine, Cardiology, Pharmacology +17